Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

In this study, patients with resistant alopecia areata treated with 35% trichloroacetic acid showed significantly better outcomes compared to those receiving superficial cryotherapy, with TCA demonstrating "excellent" results in 37.5% of cases versus 6.25% for cryotherapy.

Ozenoxacin 1% cream is an effective and safe treatment for impetigo in children and adults.

This study observed that tofacitinib therapy over about 16 weeks had a positive effect in children with alopecia areata, reducing the SALT index significantly in some patients.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

This study demonstrated a method for delivering a photosensitizer, Ammi majus fructuum furocumarines, into hair follicles using calcium carbonate particles, followed by UVA irradiation, which led to significant pigment accumulation, indicating potential improvements for photochemical therapy.

This review concluded that oral tofacitinib and adalimumab are promising treatments for cicatricial alopecia, showing effectiveness in improving signs and symptoms but requiring regular monitoring for adverse effects. The authors emphasize the need for further extensive studies to solidify these findings.

This study reported that dithranol treatment up to 3% concentration led to hair regrowth in alopecia areata patients who had previously failed ultra-potent steroids, with regrowth observed across all severity levels.

This study found that doxorubicin-induced oxidative stress downregulates FLIPs and phosphorylates EF2, sensitizing prostate cancer cells to TRAIL; antioxidants may reduce doxorubicin's effectiveness, warranting further investigation.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

This case report suggests that crisaborole may be an effective alternative treatment for alopecia areata in pediatric patients, showing significant hair regrowth after two weeks in a 10-year-old girl.

In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.

This study identified neprilysin as a potential target of the pharmacological agent arteannuin, which may guide future research into its clinical applications, although experimental verification is needed.

This study reported that intralesional triamcinolone acetonide was more effective than intralesional PRP for treating scalp alopecia areata, with minimal recurrence and side effects like atrophy and hypopigmentation.

This study found that a short-term treatment with all-trans retinoic acid may effectively stabilize platelet counts in idiopathic thrombocytopenic purpura patients experiencing fluctuations during thrombopoietin receptor agonist therapy.

This study reports two cases of alopecia areata that responded to the antihistamine fexofenadine.

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

This study investigated the effectiveness of a botanical formulation, Zauberӧl®, on testosterone-induced alopecia in Wistar rats, focusing on ingredients such as Arnica montana and Hibiscus Rosa sinensis. Results are not reported in the abstract.

This study found that baricitinib, a selective Janus kinase inhibitor, led to significantly improved scalp coverage in alopecia areata patients over 36 weeks compared to placebo, though adverse effects like acne and urinary tract infections were reported.

This article discusses baricitinib, a JAK1 and JAK2 inhibitor, as an approved and promising treatment for alopecia areata but reports no new clinical results.

This review summarizes current treatments for recalcitrant alopecia areata and recent therapeutic developments targeting specific immunological pathways, reporting no new clinical results.

This study found that all lesions in mice treated with a new topical formulation, WR 279,396, healed completely without relapse, outperforming other formulations and showing no toxicity.

This study developed a grooved microneedle platform enabling precise transdermal delivery of triamcinolone acetonide for alopecia areata, achieving accurate dosing by controlling groove position and drug concentration.

This case report describes a 64-year-old man with pulmonary nocardiosis, where erythema annulare centrifugum lesions possibly associated with co-trimoxazole resolved after discontinuation of the medication.

In this retrospective cohort study, patients using leflunomide for primary autoimmune conditions showed a decreased risk of developing alopecia areata, while those using methotrexate, cyclosporine, and rituximab had an increased risk.

In a retrospective clinical study, this research found that baricitinib is effective for alopecia areata, with 42.3% of patients achieving a significant reduction in hair loss by week 36, and 52.4% by week 52, outperforming previous trials.